<DOC>
	<DOCNO>NCT01884402</DOCNO>
	<brief_summary>Primary objective : â€¢ Develop validate tool towards patient chronic hepatitis C genotype 1 4 allow optimize treatment .</brief_summary>
	<brief_title>Observational , Prospective Study Develop Validate Prognostic Tool Optimize Therapy Patients With HCV G1/4</brief_title>
	<detailed_description>This Tool : 1 . Predicting overall impact prognostic factor ( include new factor genetic polymorphism IL28B ) Sustained Viral Response ( SVR ) . 2 . Identify patient likely respond . 3 . Therapy therefore optimize resource The validation tool check clinical practice predictive power ( consider ability calibrate discriminate ) make correct inference interpretation score obtain apply .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Patients &gt; 18 year old . Patients diagnose chronic hepatitis C presence HCV RNA plasma meet criterion initiate antiviral therapy routine clinical practice condition . Patients Genotype 1 4 . Patients result factor evaluable time inclusion . Patients accept participation study inform consent . Patients previously treat interferon ( IFN ) ribavirin ( RBV ) . Patients genotype 2 , 3 , 5 6 . Patients coinfection hepatitis B . Patients liver disease . Patients contraindication drug use treatment hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>